Prevalence and patterns of catastrophic spending for antidiabetic medication in 2020

The cost of drugs to treat diabetes in the United States is high. In this study, we looked at data from a large survey in the United States to see how much people pay for diabetes medications and insulin. We also looked at how many people spent a significant portion of their family income to make th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of managed care & specialty pharmacy 2023-10, Vol.29 (10), p.1158-1164
Main Authors: Devine, Joshua W., Lim, Dooyoung, Lugo, Amy, Farley, Joel F.
Format: Article
Language:English
Subjects:
Research Brief
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The cost of drugs to treat diabetes in the United States is high. In this study, we looked at data from a large survey in the United States to see how much people pay for diabetes medications and insulin. We also looked at how many people spent a significant portion of their family income to make these purchases. Many patients face financial barriers to accessing antidiabetic medications, especially those without insurance or with high deductibles and copayments. This can lead to poor adherence, suboptimal glycemic control, and increased risk of complications and mortality. This study provides insight into the economic burden of these treatments. The implications for managed care pharmacy are important, as pharmacists play a key role in optimizing medication therapy, educating patients, promoting adherence, and reducing costs for antidiabetic medications.
ISSN:2376-0540
2376-1032
DOI:10.18553/jmcp.2023.29.10.1158